YVYarlini Vipulanandan

Yarlini Vipulanandan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yarlini Vipulanandan has a total of 2 co-authors. Here are the top co-authors by number of shared publications:

  • Claudette Poole

    Department of Pediatrics University of Alabama at Birmingham Birmingham Alabama USA

    1 shared publication
  • David W. Kimberlin

    Department of Pediatrics University of Alabama at Birmingham Birmingham Alabama USA

    1 shared publication

Latest Publications

  • Clinical progress note: Hepatitis B

    by Yarlini Vipulanandan, Claudette Poole

    Hepatitis B virus is a well‐known infectious etiology of acute and chronic liver disease worldwide. Notably, 90% of children infected with hepatitis B in infancy develop chronic infection and subsequent progressive liver disease, including cirrhosis and hepatocellular carcinoma. Significant reduction in perinatal transmission in the United States (US) was seen after implementation of universal infant vaccination 30 years ago, as well as dramatic reductions in HBV incidence across Asia, coinciding with widespread hepatitis B vaccination. However, with ongoing changes to federal vaccine guidance and a steady rise in vaccine hesitancy, a comprehensive understanding of the epidemiology, transmission, screening, and prevention of hepatitis B remains important for pediatric health care providers.

  • Advancements and Uncertainties in the Treatment of Congenital CMV Disease

    by Yarlini Vipulanandan, David W. Kimberlin

    Congenital cytomegalovirus (CMV) is a large contributor to neurodevelopmental delay and non‐genetic related sensorineural hearing loss, which can often be delayed in onset. While a majority of CMV infections are asymptomatic in healthy children and adults, CMV infection of immunocompromised hosts and in utero infection in neonates can cause more clinically significant and potentially long‐term disease. Increased awareness of the significance of congenital CMV is reflected in the evolution of treatment recommendations over the past 20 years. Most therapeutic studies conducted thus far have focused on the treatment and outcomes of neonates with moderate to severe congenital CMV disease, while more recent studies have explored treatment for neonates and infants with CMV‐related isolated sensorineural hearing loss. This review focuses on the clinical significance and treatment of congenital CMV infection, as well as the potential role for universal newborn CMV screening.